Dystrophic Epidermolysis Bullosa – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Dystrophic Epidermolysis Bullosa Market Outlook

Thelansis’s “Dystrophic Epidermolysis Bullosa Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dystrophic Epidermolysis Bullosa treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dystrophic Epidermolysis Bullosa Overview

Dystrophic epidermolysis bullosa is one of the most common types of epidermolysis bullosa. The skin is expected to be highly fragile and to blister easily. Blisters and skin erosions result from minor injury or friction, such as scratching or rubbing. The Dystrophic epidermolysis bullosa signs and symptoms vary widely between individuals. In mild cases, blistering may primarily affect the hands, knees, feet, and elbows. Severe cases of this condition cause widespread blistering, which can result in vision loss, scarring, and other serious medical problems. Mutations cause DEB in the COL7A1 gene encoding type VII collagen. Type VII collagen is a major component of the anchoring fibril located below the basement membrane in the upper dermis, providing stable dermal-epidermal adhesion. Type VII collagen is a homotrimer composed of three proα1 (VII) chains which are encoded by the 32 kb COL7A1 gene on chromosome 3p21. DEB has two patterns of inheritance: autosomal dominant (DDEB) and autosomal recessive (RDEB). DEB has three common variants, namely, “DDEB, generalized”, “RDEB, generalized severe”, and “RDEB, generalized intermediate”, as well as other rare variants.

• The incidence of Dystrophic epidermolysis bullosa varies between 2.5 to 6.8 cases per 1,000,000 live births.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: